Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.17 -1.86%
Financial Fact:
Income tax provision (benefit): 5.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Income tax provision (benefit): 5.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
